PPT-TAVR and the Risk of Thrombosis
Author : briana-ranney | Published Date : 2018-11-03
Program Goals Thromboembolic Risk Associated With TAVR Timing of Stroke and Bleeding Post TAVR Stroke After TAVR Pathophysiology TAVR and AF Background Leaflet
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "TAVR and the Risk of Thrombosis" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
TAVR and the Risk of Thrombosis: Transcript
Program Goals Thromboembolic Risk Associated With TAVR Timing of Stroke and Bleeding Post TAVR Stroke After TAVR Pathophysiology TAVR and AF Background Leaflet Thrombosis in Bioprosthetic Aortic Valves Clinical Outcomes . Know the Signs. Listen to Your Body. . Protect Your Health.. Do You Know About. Deep Vein Thrombosis (DVT)?. . “. I never thought about getting a blood clot. But last year I broke my leg and was laid up at home. Then, I had a DVT.. Clinical Assistant Professor. Pediatric Rheumatology. September 2015. Examples of how MDs can use informatics to improve clinical care. . Using informatics tools: . 1) Augment . clinical . decisions. Thrombi . are solid masses or plugs formed in the. circulation from blood constituents. Platelets . and fibrin . form the basic . structure. . . Their . clinical significance. results from . ischaemia. Important Considerations . as TAVR Moves to . Lower-Risk Patients. Benjamin Z Galper MD MPH. Brigham & Women’s Hospital Boston MA. Consequences of Stroke. Mortality. – TAVR patients suffering a VARC-2 disabling stroke have significantly higher mortality rates compared to patients without stroke. 1-year mortality of 67% vs. 12% and 2-year mortality of 83% vs. 20%.. circulation from blood constituents. Platelets . and fibrin . form the basic . structure. . . Their . clinical significance. results from . ischaemia. from local vascular. Obstruction. . or distant . Know the Signs. Listen to Your Body. . Protect Your Health.. Do You Know About. Deep Vein Thrombosis (DVT)?. . “. I never thought about getting a blood clot. But last year I broke my leg and was laid up at home. Then, I had a DVT.. Professor & Vice-Chairman Department of Neurosurgery. Director Neurosurgical Stroke Service, . Kaleida. Health. Chief Medical Officer, Jacobs Institute. Presenting endorsed statement from. American Association of Neurological Surgeons (AANS). Rudolph Virchow, 1821-1902. Vessel wall injury. Stasis of blood. Hypercoagulability of blood. Arterial Thrombosis - 1. Interruption of blood flow causes . ischemic necrosis of involved . organ/limb. Vessel wall injury (. ”. Muhammad Raza, MD, FACC, FSCAI, RPVI.. Interventional cardiologist. Director, Cardiac Cath Lab, . Crozer. Chester Medical Center,. Upland, PA. . Disclosure. Consultant and Proctor – Medtronic. Assistant lecturer :. Noor Wafaa Hashim. Thrombosis is the development of a ‘thrombus’ consisting of platelets, fibrin, red cells and white cells in the arterial or venous circulation. If part of this thrombus in the venous circulation breaks off and enters the right heart, it may be lodged in the pulmonary arterial circulation, causing . Shilpa Shelton, MBA. Program Director, . Bluhm. Cardiovascular Institute. Northwestern Medicine. “Back to the Basics: Coding, Documentation, Coverage”. Disclaimer. The information provided is the experience of the . A Heart Team Perspective. Interventional cardiology: . Megan Coylewright, MD MPH FSCAI. Dartmouth-Hitchcock Heart and Vascular Center. Cardiac surgery: . Melissa Levack, MD. Vanderbilt University Medical Center. Diagnosis and Management in the Family Medicine Setting. Pascal Bastien, MD FRCPC. On behalf of Thrombosis . Canada. Pascal . Bastien . has received . fees/honoraria from the following sources:. Sanofi. Low-risk Randomized Trial. Michael J. Mack, . MD & . Martin B. Leon, MD. on behalf of the PARTNER 3 Trial Investigators. Disclosures - Michael J. Mack, MD. ACC 2020; Chicago, IL; March 28–30, 2020.
Download Document
Here is the link to download the presentation.
"TAVR and the Risk of Thrombosis"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents